Deutsche Bank Ag\ Lyell Immunopharma, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 82,441 shares of LYEL stock, worth $53,586. This represents 0.0% of its overall portfolio holdings.

Number of Shares

82,441

Previous 58,320 41.36%

Holding current value

$53,586

Previous $84,000 34.52%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$1.13 - $1.88 $27,256 - $45,347	24,121 Added 41.36%	82,441 $113,000
Q2 2024 Aug 14, 2024	SELL	$1.3 - $3.01 $18,457 - $42,735	-14,198 Reduced 19.58%	58,320 $84,000
Q1 2024 May 15, 2024	BUY	$1.71 - $3.07 $4,293 - $7,708	2,511 Added 3.59%	72,518 $161,000
Q4 2023 Feb 14, 2024	SELL	$1.39 - $2.35 $3,217 - $5,440	-2,315 Reduced 3.2%	70,007 $135,000
Q3 2023 Nov 09, 2023	BUY	$1.45 - $3.35 $17,545 - $40,535	12,100 Added 20.09%	72,322 $106,000
Q2 2023 Aug 14, 2023	SELL	$1.89 - $3.86 $86,450 - $176,560	-45,741 Reduced 43.17%	60,222 $191,000
Q1 2023 May 15, 2023	BUY	$1.97 - $3.58 $61,136 - $111,101	31,034 Added 41.42%	105,963 $250,000
Q4 2022 Feb 13, 2023	BUY	$2.78 - $8.09 $3,210 - $9,343	1,155 Added 1.57%	74,929 $260,000
Q3 2022 Nov 14, 2022	SELL	$5.54 - $8.27 $44,497 - $66,424	-8,032 Reduced 9.82%	73,774 $541,000
Q2 2022 Aug 11, 2022	BUY	$3.68 - $6.8 $3,323 - $6,140	903 Added 1.12%	81,806 $533,000
Q1 2022 May 13, 2022	BUY	$5.05 - $7.7 $336,102 - $512,473	66,555 Added 463.86%	80,903 $409,000
Q4 2021 Feb 11, 2022	BUY	$7.13 - $15.19 $5,361 - $11,422	752 Added 5.53%	14,348 $111,000
Q3 2021 Nov 04, 2021	BUY	$11.0 - $17.95 $149,556 - $244,048	13,596 New	13,596 $201,000

Others Institutions Holding LYEL

# of Institutions

122

Shares Held

142M

Call Options Held

18.1K

Put Options Held

200

View Full List

About Lyell Immunopharma, Inc.

Ticker LYEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 247,824,992
Market Cap $161M
Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...

More about LYEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account